Clinical trials: Hydroxychloroquine, active
Sudden Hearing Loss
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours.
- Trial name
- NCT06467526
- Testing
- Hydroxychloroquine, Steroid
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Aging
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
This study tests whether certain medicines and a skin treatment can slow down or partly reverse the body's aging process. As people age, the activity of their genes changes in predictable ways.
- Trial name
- NCT07888595
- Testing
- Topical anti-aging peptide serum
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Frontiers in Bioscience Research Institute and Aging
Breast Cancer
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in…
- Trial name
- PALAVY (NCT04841148)
- Testing
- HCQ, Avelumab, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
IgA Nephropathy
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public…
- Trial name
- QUIgAN (NCT06350630)
- Testing
- Hydroxychloroquine Oral Tablet
- Where
- 8 sites in France
- Volunteers
- 334 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Rheumatic Fever, Rheumatic Heart Disease in Children
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
The ACT4RHD trial is a multicentre, pragmatic, multi-arm, open-label adaptive platform trial addressing multiple therapeutic questions in patients with ARF and carditis.
- Conditions
- Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease
- Trial name
- ACT4RHD (NCT07830108)
- Testing
- Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 600 people
- Sponsor
- Starship Child Health, Te Toka Tumai Auckland
Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
The goal of this clinical trial is to learn if combined treatment of levothyroxine and hydroxychloroquine would improve the live birth of euthyroid women with thyroid peroxidase antibodies and unexplained recurrent pregnancy…
- Trial name
- QT-LIFE (NCT06652113)
- Testing
- hydroxychloroquine and levothyroxine, Levothyroxine
- Where
- 2 sites in China
- Volunteers
- 796 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Interstitial Lung Disease
Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
- Trial name
- TIPS (NCT07443436)
- Testing
- Azithromycin 250 mg x3/week (3 tablets/week), Prednisone 10 mg/day, Hydroxychloroquine 400 mg/day
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic…
- Trial name
- LIMIT (NCT04464759)
- Testing
- Nivolumab, Hydroxychloroquine, Ipilimumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ravi Amaravadi, MD
Sarcoidosis, Pulmonary
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year).
- Trial name
- CAESAR (NCT05841758)
- Testing
- Hydroxychloroquine
- Where
- 21 sites in France
- Volunteers
- 140 people
- Sponsor
- Hospices Civils de Lyon
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase…
- Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
- Trial name
- AIMSS (NCT07825454)
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Rheumatoid Arthritis (RA)
The Effect of Nicorandil on Rheumatoid Arthritis Patients
The aim of this clinical trial is to determine whether nicorandil works in minimizing disease severity in patients with rheumatoid arthritis. The study will also assess the safety and tolerability of nicorandil.
- Trial name
- NCT07730723
- Testing
- Nicorandil Oral Tablet, conventional synthetic antirheumatic drugs (cDMARDs)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with…
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Trial name
- NCT04201457
- Testing
- Dabrafenib, Trametinib, Hydroxychloroquine
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Pediatric Brain Tumor Consortium
Acute Myeloid Leukemia
Hydrochloroquinine & Decitabine With Venetoclax in AML
Phase I: Primary Objective: Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of the o-Dec, ven, and HCQ Secondary Objectives: Characterize the safety profile of the triplet Estimate the efficacy of…
- Trial name
- NCT07814339
- Testing
- Hydroxychloroquine, Venetoclax, Oral Decitabine/cedazuridine
- Volunteers
- 18 people
- Sponsor
- Rutgers, The State University of New Jersey
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
This phase I trial studies the side effects and the best dose of Akt inhibitor MK2206 together with hydroxychloroquine in treating patients with advanced solid tumors, melanoma, prostate or kidney cancer.
- Conditions
- Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- NCT01480154
- Testing
- Akt Inhibitor MK2206, Hydroxychloroquine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Preeclampsia
The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia
This study is prospective, single arm group ,open label, and multicenter trial (with two parallel-group [Hydroxychloroquine 200mg with Aspirin 100mg or Aspirin 100mg])
- Trial name
- HUGS (NCT05287321)
- Testing
- Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Yoo-min Kim
Lyme Borreliosis, Nervous System
Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study.
The goal of this clinical trial is to learn if hydroxychloroquine works to treat long-term complaints attributed to Lyme borreliosis in adults.
- Trial name
- DoBo (NCT07230028)
- Testing
- Hydroxychloroquin, Doxycycline
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Systemic Lupus Erythematosus
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms.
- Trial name
- SHIELD (NCT05799378)
- Testing
- Hydroxychloroquine
- Where
- 12 sites in United States
- Volunteers
- 330 people
- Sponsor
- NYU Langone Health
Melanoma Metastatic, NRAS Mutation
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma.
- Trial name
- NCT07750067
- Testing
- Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Lupus Nephritis
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children
The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
- Trial name
- NCT07675291
- Testing
- rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide
- Volunteers
- 112 people
- Sponsor
- Nanfang Hospital, Southern Medical University